Codexis has agreed to manufacture 50 grams of siRNA using its proprietary ECO Synthesis manufacturing platform to support ...

Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. The engagement represents an important demonstration of the platform's ability to ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

Researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...